Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30345116 | 1.00 | TRPA1 (0.35) | TRPA1ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL12444206 | 0.85 | EGFR (0.36) | TSHR | |
| SCHEMBL17151857 | 0.81 | TAAR1 (0.31) | — | |
| SCHEMBL17151870 | 0.81 | TRPA1 (0.35) | TRPA1ALDH1A1TSHR | |
| SCHEMBL11484838 | 0.80 | TRPA1 (0.38) | TRPA1ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL30797232 | 0.80 | TRPA1 (0.38) | TRPA1ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL338059 | 0.77 | TRPA1 (0.39) | TRPA1ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL29886015 | 0.77 | TRPA1 (0.39) | TRPA1ALDH1A1TSHRCYP4F2CYP4A11 | |
| SCHEMBL28419 | 0.76 | BACE1 (0.41) | — | |
| SCHEMBL30336913 | 0.76 | HRH3 (0.46) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME LLC | 2023-06-15 | — | — | US | disclosed |
| WO-2021226003-A1 | IL4I1 INHIBITORS AND METHODS OF USE | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | WO | disclosed |
| WO-2015152128-A1 | AMINO ACID PRECURSOR, AMINO ACID, AND PRODUCTION METHOD FOR AMINO ACID, AND PET DIAGNOSTIC TRACER USING AMINO ACID | 長瀬産業株式会社 | 2015-10-08 | — | — | WO | disclosed |
| EP-1389194-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-02-18 | — | — | EP | disclosed |
| US-20030095958-A1 | Inhibitors of bace | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-22 | — | — | US | disclosed |
| WO-2002088101-A2 | INHIBITORS OF BACE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030095958-A1 | Inhibitors of bace | BACE2, BACE1, APP | TRPA1 4457/4885ALDH1A1 2007/4885TSHR 4868/4885 |
| US-20230183214-A1 | IL4I1 INHIBITORS AND METHODS OF USE | IL4I1, IL4, IL2 | TRPA1 4407/4885ALDH1A1 471/4885TSHR 3051/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | TRPA1 4407/4885ALDH1A1 471/4885TSHR 3051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.